THOMAS LUCAS: Open Payments
NPI 1568411411 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,983 in 135 payments from 22 companies in 2025. Trend: 2023 $2,813 · 2024 $2,211 · 2025 $2,983
Food & beverage: $2,833Consulting: $150
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $405 |
| Corium, LLC | 11 | $292 |
| Axsome Therapeutics, Inc. | 10 | $291 |
| Alkermes, Inc. | 11 | $288 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $263 |
| Otsuka America Pharmaceutical, Inc. | 15 | $187 |
| Teva Pharmaceuticals USA, Inc. | 7 | $180 |
| Supernus Pharmaceuticals, Inc. | 9 | $179 |
| Lundbeck LLC | 6 | $162 |
| JAZZ PHARMACEUTICALS INC. | 1 | $150 |
Products named: VRAYLAR, REXULTI, Azstarys, Auvelity, CAPLYTA, ARISTADA, AUSTEDO XR, Qelbree.
Industry payments across TX — which companies pay providers there.
